Mirum Pharmaceuticals (NASDAQ: MIRM) insider sells vested RSUs totaling multiple transactions

Rhea-AI Filing Summary

Mirum Pharmaceuticals reported reported transactions of Common Stock under Form 144 by Christopher Peetz. The filing lists three dispositions: 7,098 shares on 01/22/2026, 6,831 shares on 01/26/2026, and 9,108 shares on 02/02/2026. The shares are described as Restricted Stock Units vesting under registered plan, issued as compensation for services.

Insights

Corporate Governance Analyst

Routine insider dispositions of vested RSUs reported via Form 144.

The excerpt shows three separate sales by Christopher Peetz totaling reported transactions of 7,098, 6,831, and 9,108 shares on the listed dates. The securities are described as Restricted Stock Units vesting under registered plan, indicating compensation-related origin.

These entries are procedural disclosures of sales; cash‑flow recipients and any trading plan references are not shown in the provided text. Subsequent filings or transaction confirmations would show sale proceeds and whether sales were pre-arranged.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC 1 New York Plaza, 8th Floor New York NY 10004	40985	3796850.40	60341617	03/16/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	03/15/2026	Restricted Stock Units vesting under registered plan	Issuer			40985	03/15/2026	Compensation for services rendered to Issuer

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Christopher Peetz c/o Mirum Pharmaceuticals, Inc. 989 E Hillsdale Blvd., Suite 300 Foster City CA 94404	Common Stock	01/22/2026	7098	662422.46
Christopher Peetz c/o Mirum Pharmaceuticals, Inc. 989 E. Hillsdale Blvd., Suite 300 Foster City CA 94404	Common Stock	01/26/2026	6831	657087.57
Christopher Peetz c/o Mirum Pharmaceuticals, Inc. 989 East Hillsdale Boulevard, Suite 300 Foster City CA 94404	Common Stock	02/02/2026	9108	940888.28

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did Mirum Pharmaceuticals (MIRM) disclose in the Form 144?

The Form 144 discloses three sales by Christopher Peetz: 7,098 shares on 01/22/2026, 6,831 on 01/26/2026, and 9,108 on 02/02/2026. The shares arose from restricted stock units vesting under a registered plan as compensation.

Were the sold shares tied to compensation or open‑market purchases?

The filing states the securities are Restricted Stock Units vesting under registered plan, indicating they were compensation awards that vested. The excerpt does not state whether sales were open‑market or executed under a trading plan.

How much cash did Christopher Peetz receive from the reported sales?

The excerpt includes dollar values next to each sale: $662,422.46, $657,087.57, and $940,888.28. Those figures correspond to the three reported dispositions on the listed dates in the filing.

Does Form 144 mean Mirum issued new shares or diluted existing holders?

Form 144 reports resale of securities by an affiliate; the document shows dispositions of vested RSUs. The filing itself does not state any issuance or dilution event for the company beyond the compensation vesting described.

Who is the reporting person in this filing?

The reporting person named in the excerpt is Christopher Peetz, with an address c/o Mirum Pharmaceuticals in Foster City, California. He is listed as the seller of the disclosed Common Stock transactions.